A randomised controlled trial of Pre-Operative Oncotype DX testing in early-stage breast cancer (PRE-DX study) – Study protocol
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0300339 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift PLOS ONE, 2024. Verfasst von Matthew Northgraves und 9 weiteren Autor:innen. Beteiligte Einrichtung: Hull Health Trials Unit, University of Hull, Hull, United Kingdom. Hauptthemen laut MEDLINE: Breast Neoplasms, Carcinoma. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Exact Sciences.
Abstract (Originalsprache)
Background
The Oncotype DX® Breast Recurrence Score assay can guide recommendations made to patients with oestrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer regarding post-surgery adjuvant therapy. Standard practice is to order the test in the post-operative setting on a specimen from the excised invasive carcinoma. However, it has been shown to be technically possible to perform the test on the diagnostic core biopsy. By testing the diagnostic core biopsy in the pre-operative setting, the wait for excised invasive carcinoma Recurrence Score results could be reduced allowing patients to be more accurately counselled regarding their treatment pathway sooner with any adjuvant treatment recommendations expedited. This would allow for more efficient streaming of follow up appointments. The aim of this study is to compare the impact on the patient treatment pathway of performing the Oncotype DX® test on the diagnostic core biopsy pre-operatively (intervention) as opposed to the excised invasive carcinoma (control). Methods and analysis This parallel group randomised controlled trial aims to recruit 330 newly diagnosed patients with grade 2 or grade 3, ER+, HER2-, invasive intermediate risk early-stage breast cancer. Participants will be randomised 2:1 to the preoperative testing of the diagnostic core biopsy compared to the post-operative testing of the excision specimen. The primary endpoint is number of clinical touchpoints between treating team and patient from initial approach until offer and prescription of the first adjuvant treatment. Secondary endpoints include time from diagnosis to offer and prescription of the first adjuvant treatment, patient-reported anxiety scores and health cost impact analysis collected at baseline, following the post-operative clinic and following the offer of adjuvant treatment, and number of alterations in treatment sequence from original planned surgical treatment to neoadjuvant therapy.
Trial registration
The study was registered on ISRCTN ( ISRCTN14337451 ) on the 16 th August 2022.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Hull Health Trials Unit, University of Hull, Hull, United Kingdom.
- Nightingale Breast Centre, Manchester University NHS Foundation Trust, Manchester, United Kingdom.
- Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom.
- Institute for Clinical and Applied Health Research (ICAHR), University of Hull, Hull, United Kingdom.
- Institute of Systems, Molecular and Integrative Biology, Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, United Kingdom.
- The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, United Kingdom.
ORCID-Profile: Matthew Northgraves, James Harvey
Förderung
- Exact Sciences
Zitieren
APA
Northgraves, M., Cohen, J., Harvey, J., Huang, C., Palmieri, C., Pinder, S., Roy, P., Reynia, S., Soares, M., & Cain, H. (2024). A randomised controlled trial of Pre-Operative Oncotype DX testing in early-stage breast cancer (PRE-DX study) – Study protocol. PLOS ONE. https://doi.org/10.1371/journal.pone.0300339
Vancouver
Northgraves M, Cohen J, Harvey J, Huang C, Palmieri C, Pinder S, et al. A randomised controlled trial of Pre-Operative Oncotype DX testing in early-stage breast cancer (PRE-DX study) – Study protocol. PLOS ONE. 2024. doi:10.1371/journal.pone.0300339
BibTeX
@article{Northgraves2024,
author = {Northgraves, Matthew and Cohen, Judith and Harvey, James and Huang, Chao and Palmieri, Carlo and Pinder, Sarah and Roy, Pankaj and Reynia, Sarah and Soares, Marta and Cain, Henry},
title = {A randomised controlled trial of Pre-Operative Oncotype DX testing in early-stage breast cancer (PRE-DX study) – Study protocol},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0300339}
}
EUVIMED